| 1 |
Shao H, Han X, Zhao J, Sun J, Fang Z, Xiong B, Zhu X, Ren W, Yuan M, Yu S, Niu M, Lv W, Zhang X, Zhang C, Li L, Luo X, Song Y, Ma Y, Dang T, Xiang H, Jin Y, Xue H, Jin G, Li X, Li J, Zhou S, Yu C, He S, Yu L, Zu H, Ma J, Lei Y, Xu K, Qi X, CHESS‐TIPS consortium. Status of transjugular intrahepatic portosystemic shunt for portal hypertension in China: A national survey analysis. Portal Hypertension & Cirrhosis 2023. [DOI: 10.1002/poh2.40] [Reference Citation Analysis]
|
| 2 |
Ma L, Liu Y, Yan Z, Zhang W, Zhang Z, Yang M, Yu J, Zhou X, Chen S, Wang J, Ma J, Luo J. Comparing the predictive ability of portoatrial and portocaval gradient after transjugular intrahepatic portosystemic shunt creation for variceal rebleeding. J Gastroenterol 2023. [PMID: 36892638 DOI: 10.1007/s00535-023-01977-w] [Reference Citation Analysis]
|
| 3 |
Ferral H, Schepis F, Gaba RC, Garcia-Tsao G, Zanetto A, Perez-Campuzano V, Haskal ZJ, Garcia-Pagan JC. Endovascular Assessment of Liver Hemodynamics in Patients with Cirrhosis Complicated by Portal Hypertension. J Vasc Interv Radiol 2023;34:327-36. [PMID: 36516940 DOI: 10.1016/j.jvir.2022.12.014] [Reference Citation Analysis]
|
| 4 |
Nadim MK, Garcia-Tsao G. Acute Kidney Injury in Patients with Cirrhosis. N Engl J Med 2023;388:733-45. [PMID: 36812435 DOI: 10.1056/NEJMra2215289] [Reference Citation Analysis]
|
| 5 |
Giri S, Patel RK, Varghese J, Agarwal D, Tripathy T. Comparative outcome of transjugular intrahepatic portosystemic shunt with or without variceal obliteration: a systematic review and meta-analysis. Abdom Radiol (NY) 2023. [PMID: 36821005 DOI: 10.1007/s00261-023-03843-y] [Reference Citation Analysis]
|
| 6 |
Queck A, Schwierz L, Gu W, Ferstl PG, Jansen C, Uschner FE, Praktiknjo M, Chang J, Brol MJ, Schepis F, Merli M, Strassburg CP, Lehmann J, Meyer C, Trebicka J. Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS. Hepatology 2023;77:466-75. [PMID: 35869810 DOI: 10.1002/hep.32676] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 7 |
Deltenre P, Zanetto A, Saltini D, Moreno C, Schepis F. The role of transjugular intrahepatic portosystemic shunt in patients with cirrhosis and ascites: Recent evolution and open questions. Hepatology 2023;77:640-58. [PMID: 35665949 DOI: 10.1002/hep.32596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Dantas Machado AC, Ramos SF, Gauglitz JM, Carpenter AM, Petras D, Aksenov AA, Kim UB, Lazarowicz M, Giustini AB, Aryafar H, Vodkin I, Warren C, Dorrestein PC, Zarrinpar A, Zarrinpar A. Pre- and Post-Portosystemic Shunt Placement Metabolomics Reveal Molecular Signatures for the Development of Hepatic Encephalopathy. medRxiv 2023:2023. [PMID: 36711444 DOI: 10.1101/2023.01.02.22281374] [Reference Citation Analysis]
|
| 9 |
Xu X, Fu Y, Jiang M, Wu M, Wu J, Meng Q. The effects and safety of anticoagulation or antiplatelet therapy following TIPS in cirrhotic patients with portal hypertension: A meta-analysis. Front Pharmacol 2023;14:1116177. [PMID: 36891262 DOI: 10.3389/fphar.2023.1116177] [Reference Citation Analysis]
|
| 10 |
Gou X, Jia W, He C, Yuan X, Niu J, Xu J, Han N, Zhu Y, Wang W, Tie J. Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients. Eur Radiol 2022. [PMID: 36576548 DOI: 10.1007/s00330-022-09357-3] [Reference Citation Analysis]
|
| 11 |
Lim HI, Cuker A. Thrombocytopenia and liver disease: pathophysiology and periprocedural management. Hematology Am Soc Hematol Educ Program 2022;2022:296-302. [PMID: 36485111 DOI: 10.1182/hematology.2022000408] [Reference Citation Analysis]
|
| 12 |
Shah RJ, Alqadi MM, Duvvuri M, Kim YJ, Tyagi R, Lokken RP, Gaba RC. Clinical Outcomes and Patency after Transjugular Intrahepatic Portosystemic Shunt Reduction for Overshunting Adverse Events. J Vasc Interv Radiol 2022;33:1507-12. [PMID: 35964879 DOI: 10.1016/j.jvir.2022.08.007] [Reference Citation Analysis]
|
| 13 |
Philipp M, Blattmann T, Bienert J, Fischer K, Hausberg L, Kröger JC, Heller T, Weber MA, Lamprecht G. Transjugular intrahepatic portosystemic shunt vs conservative treatment for recurrent ascites: A propensity score matched comparison. World J Gastroenterol 2022; 28(41): 5944-5956 [DOI: 10.3748/wjg.v28.i41.5944] [Reference Citation Analysis]
|
| 14 |
Ma L, Ma J, Zhang W, Liu Q, Zhang Z, Yang M, Yu J, Zhou X, Chen S, Wang J, Luo J, Yan Z. Predictive power of portal pressure gradient remeasured shortly after transjugular intrahepatic portosystemic shunt. Hepatol Int 2022. [DOI: 10.1007/s12072-022-10440-6] [Reference Citation Analysis]
|
| 15 |
Odriozola A, Puente Á, Cuadrado A, Rivas C, Anton Á, González FJ, Pellón R, Fábrega E, Crespo J, Fortea JI. Portal Vein Thrombosis in the Setting of Cirrhosis: A Comprehensive Review. JCM 2022;11:6435. [DOI: 10.3390/jcm11216435] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 16 |
Helzberg JH, Henson JB, Muir AJ. Recent updates in preemptive transjugular intrahepatic portosystemic shunt for acute variceal bleeding. Clin Liver Dis (Hoboken) 2022;20:97-101. [PMID: 36187370 DOI: 10.1002/cld.1243] [Reference Citation Analysis]
|
| 17 |
Hyodo R, Takehara Y, Naganawa S. 4D Flow MRI in the portal venous system: imaging and analysis methods, and clinical applications. Radiol med 2022. [DOI: 10.1007/s11547-022-01553-x] [Reference Citation Analysis]
|
| 18 |
Regner KR, Kanduri SR, Velez JCQ. Management of AKI in Patients with Cirrhosis. Curr Treat Options Gastro 2022;20:295-315. [DOI: 10.1007/s11938-022-00398-7] [Reference Citation Analysis]
|
| 19 |
Tripathi D, Bureau C. Prophylactic embolization of large spontaneous portosystemic shunts with transjugular intrahepatic portosystemic shunt (TIPS): A panacea for post-TIPS hepatic encephalopathy? Hepatology 2022;76:551-3. [PMID: 35429167 DOI: 10.1002/hep.32525] [Reference Citation Analysis]
|
| 20 |
Liu Y, Mu Z, Xiong W, Hu H, Liu A, An X, Xu Y, Yu H, Wang J, Wang J, Xiao X, Chen D, Wen L. Comparison of survival prediction values of different scoring models for patients undergoing transjugular intrahepatic portal shunt: A multicenter retrospective study. Portal Hypertension & Cirrhosis 2022;1:107-115. [DOI: 10.1002/poh2.24] [Reference Citation Analysis]
|
| 21 |
Lv Y, Chen H, Luo B, Bai W, Li K, Wang Z, Xia D, Guo W, Wang Q, Li X, Yuan J, Cai H, Xia J, Yin Z, Fan D, Han G. Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial. Hepatology 2022;76:676-88. [PMID: 35266571 DOI: 10.1002/hep.32453] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 22 |
Yao X, He S, Wei M, Qin JP. Influence of different portal vein branches on hepatic encephalopathy during intrahepatic portal shunt via jugular vein. World J Gastroenterol 2022; 28(31): 4467-4470 [DOI: 10.3748/wjg.v28.i31.4467] [Reference Citation Analysis]
|
| 23 |
Ha HI. Massive Hemobilia Due to Arteriobiliary Fistula after the Transjugular Intrahepatic Portosystemic Shunt (TIPS): A Case Report. Korean J Abdom Radiol 2022;6:63-67. [DOI: 10.52668/kjar.2022.00122] [Reference Citation Analysis]
|
| 24 |
Lv Y, Chen H, Luo B, Bai W, Li K, Wang Z, Xia D, Guo W, Wang Q, Li X, Yuan J, Cai H, Xia J, Yin Z, Fan D, Han G. Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00087-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 25 |
Chen XL, Yao X, Yang GD, Qin JP. Applications of vascular interventions in hypersplenism in liver cirrhosis. Shijie Huaren Xiaohua Zazhi 2022; 30(3): 140-146 [DOI: 10.11569/wcjd.v30.i3.140] [Reference Citation Analysis]
|
| 26 |
Kaewput W, Thongprayoon C, Dumancas CY, Kanduri SR, Kovvuru K, Kaewput C, Pattharanitima P, Petnak T, Lertjitbanjong P, Boonpheng B, Wijarnpreecha K, Zabala Genovez JL, Vallabhajosyula S, Jadlowiec CC, Qureshi F, Cheungpasitporn W. In-hospital mortality of hepatorenal syndrome in the United States: Nationwide inpatient sample. World J Gastroenterol 2021; 27(45): 7831-7843 [PMID: 34963745 DOI: 10.3748/wjg.v27.i45.7831] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 27 |
Tai Y, Zhao C, Zhang L, Tang S, Jia X, Tong H, Liu R, Tang C, Gao J. Celecoxib reduces hepatic vascular resistance in portal hypertension by amelioration of endothelial oxidative stress. J Cell Mol Med 2021;25:10389-402. [PMID: 34609050 DOI: 10.1111/jcmm.16968] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
